



Esperion Therapeutics, Inc.
Investor Relations Department
3891 Rancho Drive
Suite 150
Ann Arbor, MI 48108
United States

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: ESPR


Last Trade:	69.01
Trade Time:	1:20 PM ET Apr 26, 2018
Change:	-0.24 (-0.347%)
Day Range	68.54 - 70.41
52-Week Range	30.95 - 82.68
Volume	117,152

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Esperion is a late-stage pharmaceutical company passionately committed to developing and commercializing complementary, non-statin, once-daily, oral therapies to lower elevated low density lipoprotein (LDL) cholesterol for patients with hypercholesterolemia not adequately treated with current lipid-modifying therapies. Bempedoic acid, a convenient, complementary, cost-effective, once-daily, oral inhibitor of ATP Citrate Lyase (ACLi) brings a targeted mechanism of action to address patients unmet medical needs in a way that is "patient-friendly, physician-frie... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Apr 13, 2018*
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)
- Mar 27, 2018*
[Esperion Announces Positive Top-Line Results from Phase 2 Study of Bempedoic Acid Added-On to a PCSK9 Inhibitor in Patients with Hypercholesterolemia](#)
- Mar 7, 2018*
[Esperion to Participate in Fireside Chat at March 2018 Investor Conferences](#)
- Mar 7, 2018*
[Esperion Announces Positive Top-Line Results from First Pivotal Phase 3 Study of Bempedoic Acid](#)
- Feb 23, 2018*
[Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635\(c\)\(4\)](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 20, 2018*
[Annual Report \(10-K\)](#)
- Apr 13, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Nov 7, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 4, 2017*
[Quarterly Report \(10-Q\)](#)